Company Information
CIN
Status
Date of Incorporation
24 February 2006
State / ROC
Mumbai / ROC Mumbai
Last Balance Sheet
31 March 2023
Last Annual Meeting
25 August 2023
Paid Up Capital
569,980,000
Authorised Capital
1,119,980,000
Directors
Sumit Gupta
Director/Designated Partner
over 2 years ago
over 2 years ago
Neeraj Singh
Director/Designated Partner
over 2 years ago
over 2 years ago
Amit Bansilal Jain
Director/Designated Partner
over 2 years ago
over 2 years ago
Abhijit Basu
Director/Designated Partner
over 2 years ago
over 2 years ago
Prabir Purkayastha
Director
about 15 years ago
about 15 years ago
Past Directors
Vivek Gupta
Director
almost 4 years ago
almost 4 years ago
Samir Kumar
Director
almost 4 years ago
almost 4 years ago
Junaid Waheed
Director
about 12 years ago
about 12 years ago
Khalid Mahmood
Director
about 17 years ago
about 17 years ago
Susheel Koul
Director
about 17 years ago
about 17 years ago
Sameer Ashok Paigankar
Director
over 18 years ago
over 18 years ago
Anand P Shah
Director
over 18 years ago
over 18 years ago
Murali Venkata Krishna Sistla
Director
almost 20 years ago
almost 20 years ago
Patents
The present invention provided a process of preparing amorphous form of vilazodone hydrochloride from crystalline vilazodone hydrochloride by a simple precipitation process.
The present invention relates to an improved process for preparation of Felbamate compound of structural formula I comprising reacting a compound of structural formula II with sodium cyanate in the presence of dry hydrochloric acid in methylene dichloride solvent and isolating Felbamate compound of structural formul...
The present invention provides a process for the preparation of pure hydralazine hydrochloride.
A process of preparing crystalline Form VI of agomelatine comprises crystallizing agomelatine in water or a mixture of water and N, N!-dimethylformamide solvent.
The process for the preparation of rosuvastatin or pharmaceutically acceptable salts thereof using novel intermediates of structural formula VIII and X is provided.
Formula V111 Formula X
The present invention provides an improved process for the preparation of substantially pure nepafenac compound of structural formula I.
An improved process for the preparation of reboxetine and its pharmaceutically acceptable salts by the use of intermediate compounds of structural formula V, VI or VII is provided.
Formula V Formula VI Formula VII
Wherein P is a nitrogen protection group
An Improved Process For The Preparation Of Prasugrel And Its Pharmaceutically Acceptable Salts There
An improved process for the preparation of prasugrel compound of structural formula-I and its pharmaceutically acceptable salts thereof is provided. The process comprises treating a compound of structural formula IX with trifluoromethane sulfonic acid to get a compound of structural formula X and then converting com...
The present invention relates to a novel crystalline form II of argatroban, to processes of preparing crystalline form II of argatroban and pharmaceutical composition thereof.
The present invention provides a process for the preparation of ospemifene of structural formula I comprises the steps of reacting compound of structural formula VIII with compound of structural formula XI .
X = Cl, Br, I, mesyloxy, tosyloxy or any other good leaving group
The present invention relates to novel crystalline form F of moxifloxacin hydrochloride, to processes for preparing crystalline form F of moxifloxacin hydrochloride and pharmaceutical composition thereof.
The present invention relates to a process for the preparation of substantially pure fampridine compound of structural formula I comprising nitrifying pyridine-N-oxide hydrochloride with suitable nitrating agent; reducing with suitable reducing agent and purifying by recrystallizing in water followed by treating wit...
The present invention provided processes of preparing ethacrynate sodium monohydrate form.
ABSTRACT
The present invention relates to novel processes for the preparation of HMG-CoA reductase inhibitors such as atorvastatin; cerivastatin; fluvastatin; pitavastatin and rosuvastatin. The processes comprises the converting a compound of structural formula I into a compound of structural formula]].
single ...
The present invention provides an improved process for the preparation of perphenazine
compound of structural formula I.
An improved process for the preparation of lacosamide compound of structural formula I, wherein N-Boc-protected-D-serine ("Boc1" refers to t-butoxycarbonyl functional group) compound of structural formula XIT IS benzylated to produce a compound of structural formula XIX, which on rnethyiation, deprotection and acyla...
A process for the prepartion of bepotastine and its pharmaceutically acceptable salts thereof comprising: alkylating piperidine compound of structural formula VIII; hydrolyzing the resulting compound of structural formula IX into compound of structural formula X and then converting compound of structural formula X i...
The present inventions provide novel intermediate 5, 6, 7,7a-tetrahydro-thieno [3, 2-c] pyridine-2(4H)-one hydrobromide and its use in a process of preparing prasugrel and its pharmaceutically acceptable salts thereof.
The present invention provides a novel process for the preparation of eslicarbazepine, eslicarbazepine acetate and novel compounds that may be useful as intermediates in the preparation thereof.
wherein, R' is -C1 to C3 alkyl or substituted or unsubstituted phenyl or -O-C1-C3 alkyl.
The present invention provides a novel process for the preparation of amorphous form of tolvaptan active pharmaceutical ingredient. The process comprises, providing a solution of tolvaptan active pharmaceutical ingredient in an organic solvent, removing solvent from the solution of tolvaptan active pharmaceutical in...
An improved process for preparing febuxostat comprising reacting an alkyl ester of 2-(3-cyano-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylic acid with lithium hydroxide in an organic solvent.
The present invention relates to a novel process of preparing Dronedarone hydrochloride by the use of a compound of structural formula VI.
The present invention provides novel polymorphic form of ethacrynic acid herein after refer as crystalline form I and novel polymorphic form of sodium ethacrynate herein after refer as crystalline form II. The present invention further provides processes for preparing crystalline form I of ethacrynic acid and crysta...
The present invention provides a process for preparing Dapoxetine hydrochloride compound of formula I comprises alkylating compound of formula II with an alkylating agent to get a Dapoxetine compound of formula III and then converting Dapoxetine compound of formula III into Dapoxetine hydrochloride compound of formu...
The present invention provided a novel process of preparing alcaftadine compound of structural formula I by employing an intermediate compound of structural formula II.
The present invention relates to a process for the preparation of rosuvastatin calcium comprising reacting compound of structural formula V with a compound of structural formula III to get a compound of structural formula IV and then converting a compound of structural formula IV into rosuvastatin calcium compound o...
The present invention provided a process of preparing amorphous form of flngolimod hydrochloride from crystalline flngolimod hydrochloride.
The present invention relates to novel polymorph Form E of asenapine maleate, to process of their preparation, pharmaceutical composition comprising Form E of asenapine maleate and their use in therapy.
The present invention relate to a novel crystalline form of rosuvastatin calcium hereinafter designated as Form E as well as processes for its manufacture and pharmaceutical composition comprising rosuvastatin crystalline Form E, which is useful as an agent for treating hyperlipidemia, hypercholesterolemia and ather...
The present invention relate to a novel polymorphic form of strontium ranelate octahydrate designated herein as beta crystalline form. The invention further relate to methods of preparing beta crystalline form of strontium ranelate octahydrate and pharmaceutical composition comprising strontium ranelate octahydrate....
The present invention relates to a novel process for the preparing of asenapine maleate compound of structural formula I.
The present invention relates to amorphous form of Paliperidone palmitate. The present invention further relates to processes of preparing amorphous form of Paliperidone palmitate and pharmaceutical composition thereof
The present invention relates to novel polymorphs of agomelatine referred herein after as a and β crystalline form. The present invention further relate to a process of preparing a and β crystalline form of agomelatine and pharmaceutical composition thereof.
The present invention relates to a process of preparing substantially pure frovatriptan and its pharmaceutically acceptable salts thereof by the application of simulated moving bed technology.
The present invention relates to an improved process of preparing moxifloxacin hydrochloride.
The present invention relates to an improved process for the preparation of trospium chloride compound of structural formula I comprises reacting 3α-hydroxynortropane-8-spiro-1’-pyrrolidinium chloride compound of structural formula III and benzilic acid imidazolide compound of structural formula IV in dimethyl aceta...
An improved process for the preparation of tapentadol and its acid addition salts thereof. The process comprises converting a compound of structural formula II into tapentadol hydrochloride compound of structural formula I via the formation of an intermediate compound of structural formula III.
...
The present invention relates to novel 4-chlorobenzhydrylamine salt of rosuvastatin acid compound of structural formula I as well as processes for preparing substantially pure rosuvastatin calcium.
The present inventions relate to a process for preparing substantially pure montelukast sodium of formula I via the formation of montelukast strontium salt of formula III.
The present invention provides an improved process of preparing racemate or either isomer N, N-dimethyl-N-[3-(2-naphthyloxy)-3-thien-2-ylpropyl] amine and its acid addition salts thereof, an intermediate for the preparation of duloxetine and its pharmaceutically acceptable salts thereof.
The present invention relates to an improved process of preparing olopatadine and pharmaceutically
acceptable salts thereof comprising the steps of:
a. reacting ll-oxo-6, 11-dihydrodibenz [b, e] oxepin-2-acetic acid compound of structural formula II with (3-dimethylaminopropyl)-triphenylphosphonium bromide hydrobr...
A process for the purification of crude montelukast acid and its pharmaceutically acceptable salts thereof by forming the salts of crude montelukast acid with citrulline, tyrosine, glutamine, glutamic acid, histidine, lysine, methionine, phenylalanine, tryptophan, isoleucine, threonine, valine, leucine, alanine, asp...
A process of preparing of substantially pure perindopril compound of structural formula I or its pharmaceutically acceptable salts thereof having less than 0.1% weight / weight of compound of structural formula II by forming a salts of crude perindopril with L-citrulline and organic bases such as compound of structu...
A process for preparing substantially pure lymecycline compound of structural formula I having less than 0.15% weight / weight of following compound of structural formula V, VI and VII is provided.
The present invention relates to a process for the preparation of amorphous form of febuxostat Compound.
The present inventions provide 4-chlorobenzhydryl amine salts of Montelukast acid, represented by compound of structural formula V and a process for preparing Montelukast acid and pharmaceutically acceptable salts thereof free from coloring impurities comprising the steps of treating crude Montelukast acid compound ...
An improved process for the preparation of safinamide and its pharmaceutical acceptable salts thereof comprises reacting compound of structural formula II with lithium borohydride in an organic solvent to get safinamide compound of structural formula V.
The present invention provides a process for producing distrontium 5-[bis (2-oxido-2-
oxoethyl) amino]-4-cyano-3-(2-oxido-2-oxoethyl) thiophene-2-carboxylate
comprising reacting a compound of formula V with strontium hydroxide.
Formula V
wherein R5, R6, R7 and R8, which may be the same or different, each repr...
The present invention provides non hygroscopic thermodynamically stable polymorphic form A of strontium ranelate.
The present inventions relate to novel thermodynamically stable bromfenac sodium crystalline Form II, processes of their preparation and pharmaceutical composition thereof.
ABSTRACT
The present invention relates to a novel process of preparing liranaftate compound of structural formula I.
A substantially pure crystalline form A of tetrabenazine compound of structural formula I and processes for the preparation thereof is provided.
An improved process for the preparation of bepotastine and its pharmaceutical^ acceptable salts thereof. The process comprises treating the compound of structural formula II with resolving agent to get a compound of structural formula III and then converting a compound of structural formula III into bepotastine and ...
The present invention provides an improved process for the preparation of amorphous form of pitavastatin calcium.
The present invention relates to novel polymorph of dronedarone hydrochloride hereinafter refer as crystalline form II. The present invention further relates to processes for preparing crystalline form II of dronedarone hydrochloride and pharmaceutical composition thereof.
The present invention relate to an amorphous form of iloperidone. The present invention further relate to processes of preparing amorphous form of iloperidone and pharmaceutical composition thereof.
The present invention relates to novel crystalline polymorphs of tolvaptan hereinafter referred as crystalline form II and cryatalline form III. the present invention further relates to a process of preparing crystalline form 11 and crystalline form III of tolvaptan and pharmaceutical composition thereof.
...
The present invention relate to an improved process for the preparation of iloperidone compound of structural formula I comprises reacting 6-fluoro-3-(4-piperidinyl)-l, 2-benzisoxazole hydrochloride compound of structural formula II with l-[4-(3-chloropropoxy)-3-methoxyphenyl] ethanone compound of structural formula...
The present invention provides polymorphic form of regadenoson and its acid addition salts selected from the group comprising of regadenoson hydrochloride, regadenoson hydrobromide, regadenoson maleate, regadenoson fumarate, regadenoson succinate, regadenoson sulfate, regadenoson acetate, regadenoson mesylate, regad...
A process of preparing of substantially pure perindopril compound of structural formula I or its pharmaceutically acceptable salts thereof having less than 0.1% weight / weight of compound of structural formula II by forming a salts of crude perindopril with L-glutamine, L-glutamic acid, L-histidine, L-lysine, methi...
The present invention relates to novel polymorph of febuxostat hereinafter refer as β-crystalline form. The present invention further relates to processes for preparing β-crystalline form of febuxostat and pharmaceutical composition thereof.
The present invention relates to an amorphous form of agomelatine. The present invention further relate to a processes of preparing amorphous form of agomelatine and pharmaceutical composition thereof.
The present invention relates to a novel process for preparing rivaroxaban. The process comprises condensing a compound of structural formula II with compound of structural formula III to get rivaroxaban compound of structural formula I.
Formula II Formula III Formula I
The present invention relate to novel polymorphic forms of alcaftadine, processes of preparing novel polymorphic forms of alcaftadine and pharmaceutical composition thereof.
The present invention relates to a process of preparing alcaftadine compound of structural formula I by employing pure compound of structural formula VIII.
The present invention provides substantially pure compound of structural formula XXXII and compound of structural formula XXXIV.
wherein, P is benzyl, or substituted benzyl, alkyl sulfonyl, aryl sulfonyl or substituted aryl sulfonyl group
The present invention provides a novel process of preparing cinacalcet hydrochloride.
The present invention relates to novel polymorphic forms of dapoxetine hydrochloride. The present invention further relates to processes of preparing novel polymorphic forms of dapoxetine hydrochloride and pharmaceutical composition thereof.
Present invention provides a simple, economic, safe and industrially viable process for preparation of Rufinamide compound represented by structural formula I having impurity represented by structural formula II less than 0.1%.
The present invention provides an improved process for the preparation of fluphenazine or its salts or esters.
The present invention relates to an improved process of preparing substantially pure alcaftadine.
The present invention relates to a novel crystalline form of argatroban refers herein after as crystalline form III, processes of preparing crystalline form III of argatroban and pharmaceutical composition thereof.
The present invention relates to an improved process of preparing substantially pure (S, S)-2, 8-diazabicyclo [4.3,0] nonane compound of structural formula II and its conversion to moxifloxacin hydrochloride compound of structural formula I.
The present invention relates to a process for the preparation of Chlorpromazine hydrochloride of structural formula I with a high degree of purity, specifically with a low content of genotoxic impurities.
The present invention relates to the improved process of preparation of Isoproterenol hydrochloride of Formula (I).
The present invention mainly relates to an improved process for preparation of odorless and colorless Albendazole of Formula (I).
The present invention relates to an improved process for the preparation of Dofetilide of Formula I,
through the preparation of highly pure intermediate i.e. N-methyl-N-(4-nitrophenethyl)-2-(4-nitrophenoxy)ethanamine of Formula II.
The present invention relates to an improved process for the preparation of clonidine hydrochloride compound of formula (I)
An improved process for the preparation of Dronedarone intermediate 2~butyl-5-
nitrobenzofuran-3-yl)( 4-hydroxyphenyl)methanone compound of formula (II) which
is used for preparation of Dronedarone compound of formula (I).
The present invention relates to an improves process for the preparation of
Apremilast; the compound of structural formula (I)
The present invention relates to a process for the preparation of crystalline form of Dofetilide having structural formula (I).
The present invention relates to process for preparation of an amorphous form of Betrixaban maleate represented by structural formula I.
PROCESS FOR THE PREPARATION OF PITAVASTATIN CALCIUM
ABSTRACT
The present invention provides improved process for the preparation of Pitavastatin calcium represented by the following compound of formula (I).
The present invention relates to a process for the preparation of Prazosin Hydrochloride represented by compound of Formula I.
Present invention relates to an improved process for the preparation of Dorzolamide hydrochloride compound represented by structural formula I by reduction of N-((4S,6S)-6-methyl-7,7-dioxido-2-sulfamoyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-4-yl)acetamide compound represented by structural formula VI using sodium bi...
The present invention relates to an improves process for the preparation of Lifitegrast; the compound of structural formula (I)
using novel intermediate; the compound of structural formula (III).
The present invention relates to process for the preparation of substantially pure Selexipag; the compound of structural formula (I)
Present invention provides a process for the preparation of Eletriptan having compound of structural formula I and pharmaceutically acceptable salt thereof.
The present invention provides a simple, economic, safe and industrially viable process for the preparation of Tolvaptan compound represented by structural formula (I) and preparation of novel intermediate thereof; compound represented by structural formula (II).
The present invention provides process for preparation of Ramelteon; compound represented by structural formula (I) in pure (S) form comprising, enzymatic enantioselective amidation of compound represented by structural formula (VII) using enzyme.
i
The present invention relates to a process for resolution of (±) tetrabenazine
compound represented by structural formula III, to obtain the desired (R,R)-enantiomer of tetrabenazine (Formula I) and conversion of compound of formula I to Valbenazine Tosylate (Formula II).
A process for the preparation of Eletriptan hydrobromide
Present invention relates to a process for the preparation of Eletriptan hydrobromide the compound represented by the structural formula I:
The present invention relates to a process for the preparation of hydroxyzine represented by compound of Formula I and its pharmaceutically acceptable salts. The present invention further relates to the pamoate (Compound of Formula II) or hydrochloride (compound of Formula III) salt of hydroxyzine. Preferably the pr...
The present invention relates to an improved, safe, and simplified synthesis process for the preparation of Bempedoic acid without use of any pyrophoric reagents and solvents. The synthesis process disclosed herein starts with synthesis of ethyl 7-bromo-2,2-dimethylheptanoate by reacting ethyl isobutyrate with 1,5-d...
ABSTRACT
A NOVEL DOXYLAMINE FOLIATE SALT, PROCESS OF SYNTHESIS THEREOF, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
The present invention discloses a novel Doxylamine foliate salt. The present invention also
discloses a process for the synthesis of said salt and pharmaceutical compositions comprising
the...
The present invention relates to a novel diisopropylammonium salt of bempedoic acid of formula II and further its conversion to bempedoic acid.
Formula II
A PROCESS FOR PREPARATION OF BENZODIAZEPINE COMPOUND
The present invention relates to a process for preparation of benzodiazepine compound of Fonnula I
or salts thereof. More particularly, the present invention relates to a process for preparation of
Rernimazolam besylate.
Br 0-0 HO-~ I #
II
0
Formula
...
Registered Trademarks
[Class : 42] Testing, Inspection And Research Services In The Field Of Pharmaceutical, Cosmetics And Food Stuff ; Testing And Analysis Services In The Field Of Pharmaceutical, Cosmetics And Food Stuff ; Bacteriological Testing, Scientific And Industrial Research
[Class : 35] Business Management, Business Administration, Distribution Of Medicine Samples, Retailing, Wholeselling & Distribution Of Medicines And Pharmaceutical Preparations
[Class : 35] Business Management, Business Administration, Distribution Of Medicine Samples, Retailing, Wholeselling And Distribution Of Medicines And Pharmaceutical Preparations
View +19 more Brands for Enaltec Labs Private Limited.
Charges
20 May 2019
The Saraswat Co-operative Bank Limited
15 Crore
17 March 2018
Centrum Financial Services Limited
15 Crore
28 April 2017
Hdfc Bank Limited
21 Lak
28 April 2017
Hdfc Bank Limited
21 Lak
02 January 2017
Axis Bank Limited
112 Crore
24 March 2014
Union Bank Of India
112 Crore
22 November 2011
Cholamandalam Investment And Finance Company Limited
4 Lak
16 October 2012
State Bank Of Mauritius Limited
6 Crore
21 December 2012
State Bank Of Mauritius Limited
1 Crore
11 January 2011
Icici Bank Limited
24 Crore
17 December 2009
Central Bank Of India
14 Crore
31 July 2008
State Bank Of India
9 Crore
30 December 2020
Axis Bank Limited
4 Crore
29 September 2023
Others
0
20 May 2019
Others
0
02 January 2017
Axis Bank Limited
0
30 December 2020
Axis Bank Limited
0
24 March 2014
Others
0
11 January 2011
Icici Bank Limited
0
17 March 2018
Others
0
31 July 2008
State Bank Of India
0
17 December 2009
Central Bank Of India
0
28 April 2017
Hdfc Bank Limited
0
22 November 2011
Cholamandalam Investment And Finance Company Limited
0
16 October 2012
State Bank Of Mauritius Limited
0
21 December 2012
State Bank Of Mauritius Limited
0
28 April 2017
Hdfc Bank Limited
0
29 September 2023
Others
0
20 May 2019
Others
0
02 January 2017
Axis Bank Limited
0
30 December 2020
Axis Bank Limited
0
24 March 2014
Others
0
11 January 2011
Icici Bank Limited
0
17 March 2018
Others
0
31 July 2008
State Bank Of India
0
17 December 2009
Central Bank Of India
0
28 April 2017
Hdfc Bank Limited
0
22 November 2011
Cholamandalam Investment And Finance Company Limited
0
16 October 2012
State Bank Of Mauritius Limited
0
21 December 2012
State Bank Of Mauritius Limited
0
28 April 2017
Hdfc Bank Limited
0
29 September 2023
Others
0
20 May 2019
Others
0
02 January 2017
Axis Bank Limited
0
30 December 2020
Axis Bank Limited
0
24 March 2014
Others
0
11 January 2011
Icici Bank Limited
0
17 March 2018
Others
0
31 July 2008
State Bank Of India
0
17 December 2009
Central Bank Of India
0
28 April 2017
Hdfc Bank Limited
0
22 November 2011
Cholamandalam Investment And Finance Company Limited
0
16 October 2012
State Bank Of Mauritius Limited
0
21 December 2012
State Bank Of Mauritius Limited
0
28 April 2017
Hdfc Bank Limited
0
Documents
Form CHG-4-16122020_signed
Form CHG-4-15122020_signed
Letter of the charge holder stating that the amount has been satisfied-14122020
Form DPT-3-06102020-signed
Form INC-22-19092020_signed
Proof of Registered Office address(Conveyance/Lease deed/Rent Agreement along with the rent receipts) etc-16092020
Copy of board resolution authorizing giving of notice-16092020
Optional Attachment-(1)-16092020
Copies of the utility bills as mentioned above (not older than two months)-16092020
Form CHG-1-04052020_signed
CERTIFICATE OF REGISTRATION FOR MODIFICATION OF CHARGE-20200504
Optional Attachment-(1)-27042020
Particulars of all joint charge holders;-27042020
Instrument(s) of creation or modification of charge;-27042020
Form PAS-3-26022020_signed
Form MGT-14-26022020_signed
Optional Attachment-(1)-26022020
Complete record of private placement offers and acceptances in Form PAS-5.-26022020
Copy of Board or Shareholders? resolution-26022020
List of allottees. Attach separate list for each allotment (refer instruction kit for format).If not attached, then it shall be submitted separately in a CD.-26022020
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-24022020
Optional Attachment-(1)-24022020
Form SH-7-23012020-signed
Altered memorandum of assciation;-15012020
Copy of the resolution for alteration of capital;-15012020
Optional Attachment-(1)-15012020
Optional Attachment-(2)-15012020
Form MGT-7-06012020_signed
Copy of MGT-8-02012020
List of share holders, debenture holders;-02012020
